Mestranol (CID 6291) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(20)
 
 
Inactive(783)
 
 
Inconclusive(13)
 
 
Unspecified(146)
 
 
Top Targets:
7TM GPCR Srx(31)
 
 
 
7TM GPCR Srsx(20)
 
 
 
 
p450(14)
 
 
 
Bcl-2 like(11)
 
 
alkPPc(10)
 
 
BioAssay Types:
Screening(479)
 
 
 
 
Confirmatory(231)
 
 
 
 
 
Literature(95)
 
 
 
 
 
BioActivity Types:
Potency(174)
 
 
 
 
 
IC50(156)
 
 
 
 
EC50(9)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 863    Data Row: 962   Total Pages: 20   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103771134]
IC50 0.018DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
2
[SID103771134]
IC50 0.018DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
3
[SID103771134]
IC50 0.018DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
4
[SID103771134]
IC50 0.018DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) [AID625258, Type: other]Estrogen receptor [gi:544257]
View
5
[SID103771134]
IC50 0.041DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) [AID625222, Type: other]Sodium-dependent serotonin transporter [gi:400630]
View
6
[SID103771134]
IC50 0.041DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) [AID625222, Type: other]Sodium-dependent serotonin transporter [gi:400630]
View
7
[SID103771134]
IC50 0.041DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) [AID625222, Type: other]Sodium-dependent serotonin transporter [gi:400630]
View
8
[SID144204751]
Potency 0.2371qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
9
[SID144204751]
Potency 0.2371qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
10
[SID144204751]
Potency 0.2371qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT [AID686979, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
11
[SID144204751]
Potency 0.2371qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
12
[SID144204751]
Potency 0.2371qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
13
[SID144204751]
Potency 0.2371qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
14
[SID103771134]
IC50 1.382DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) [AID625207, Type: other]Sodium-dependent noradrenaline transporter [gi:128616]
View
15
[SID103771134]
IC50 1.382DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) [AID625207, Type: other]Sodium-dependent noradrenaline transporter [gi:128616]
View
16
[SID103771134]
IC50 5.601DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) [AID625225, Type: other]
View
17
[SID103771134]
IC50 10.682DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) [AID625228, Type: other]Androgen receptor [gi:113832]
View
18
[SID103771134]
IC50 10.682DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) [AID625228, Type: other]Androgen receptor [gi:113832]
View
19
[SID56422167]
Potency 20.5962qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
20
[SID56422167]
Potency 20.5962qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
21
[SID56422167]
Potency 20.5962qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT [AID686978, Type: confirmatory]TDP1 protein [Homo sapiens] [gi:79154014]
View
22
[SID103771134]
IC50 28.54DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) [AID625235, Type: other]Cannabinoid receptor 1 [gi:115562]
View
23
[SID103771134]
IC50 28.54DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) [AID625235, Type: other]Cannabinoid receptor 1 [gi:115562]
View
24
[SID103771134]
IC50 28.54DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) [AID625235, Type: other]Cannabinoid receptor 1 [gi:115562]
View
25
[SID103771134]
 Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
26
[SID103771134]
 Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
27
[SID103771134]
 Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins [AID678712, Type: Literature]Cytochrome P450 1A2 [gi:117144]
View
28
[SID103771134]
 Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins [AID678714, Type: Literature]Cytochrome P450 2C19 [gi:60416369]
View
29
[SID103771134]
 Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins [AID678714, Type: Literature]Cytochrome P450 2C19 [gi:60416369]
View
30
[SID56422167]
 qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
31
[SID56422167]
 qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
32
[SID56422167]
 qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
33
[SID56422167]
 qHTS of D3 Dopamine Receptor Agonist: qHTS [AID652048, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
34
[SID56422167]
 qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
35
[SID56422167]
 qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
36
[SID56422167]
 qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
37
[SID56422167]
 qHTS of D3 Dopamine Receptor Potentiators: qHTS [AID652051, Type: screening]DRD3 gene product [Homo sapiens] [gi:89191863]
View
38
[SID103771134]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
39
[SID103771134]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
40
[SID103771134]
 Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins [AID678713, Type: Literature]Cytochrome P450 2C9 [gi:6686268]
View
41
[SID103771134]
 Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins [AID678715, Type: Literature]Cytochrome P450 2D6 [gi:84028191]
View
42
[SID103771134]
 Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins [AID678715, Type: Literature]Cytochrome P450 2D6 [gi:84028191]
View
43
[SID8139980]
 MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators [AID1814, Type: screening]
View
44
[SID48416225]
 DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
45
[SID48421896]
 DSSTox (NCTRER) National Center for Toxicological Research Estrogen Receptor Binding Database [AID1204, Type: screening]
View
46
[SID8139980]
 HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress [AID2732, Type: screening]Ddit3 gene product [Mus musculus] [gi:160707929]
View
47
[SID8139980]
 High-content cell-based screening for modulators of autophagy [AID463193, Type: screening]microtubule-associated proteins 1A/1B light chain 3A isoform b [Homo sapiens] [gi:31563518]
View
48
[SID103771134]
IC50 84.414DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) [AID625172, Type: other]Progesterone receptor [gi:75071465]
View
49
[SID103771134]
 Oral antifertility potency (A) relative to ethynylestradiol (EE) in rats. [AID188023, Type: Literature]
View
50
[SID103771134]
 Oral estrogenic potency (E) relative to ethynylestradiol (EE) in rats [AID188024, Type: Literature]
View